The third blog in this ACCESS PrEP blog series addresses health providers’ experiences with oral PrEP services. It explores their knowledge of oral PrEP and concerns about increased risky behaviour. Health providers also expressed concern about the challenges clients faced when accessing oral PrEP and the barriers to uptake, adherence and continuation.
This narrative, the second in the ACCESS PrEP blog series, focuses on PrEP-related side effects. It highlights the determination of some clients to continue using oral PrEP despite the side effects they were experiencing.
This blog is the first in the ACCESS blog series and it gives an overview of the study findings. It explores the motivations that made clients decide to start, continue or stop using oral PrEP, as well as what made certain clients decide not to start taking oral PrEP at all.
The full spectrum of HIV-1 diversity can be found in central Africa, including two divergent HIV-1 strains collected in 1983 and 1990 in Democratic Republic of Congo (DRC) that were preliminarily classified as group M subtype L. However, a third epidemiologically distinct subtype L genome has now been identified.
The 20th International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA 2019), which took place from 2-7 December at the Kigali Convention Centre, Rwanda, represented a tremendous opportunity to highlight the diverse nature of the African region’s HIV epidemic an
Metabolic syndrome – including obesity – developed significantly more frequently in people who received dolutegravir, tenofovir alafenamide (TAF) and emtricitabine compared to other regimens in the South African ADVANCE study, Dr Michelle Moorhouse reported on Thursday at the
Tenofovir is less toxic than other nucleoside reverse-transcriptase inhibitors used in antiretroviral therapy (ART) and may improve retention of human immunodeficiency virus (HIV)–infected patients on ART.